The MFN Effect: Critical Actions to Shape Most Favored Nation Pricing Strategy
The Trump administration has elevated prescription drug pricing reform as a priority, accelerating the development of Most Favored Nation (MFN) proposals that would tie US prices to lower-cost international benchmarks. Such a shift could significantly reshape global pricing dynamics, revenue distribution, and manufacturers’ launch and market access strategies. This white paper outlines the potential implications of MFN policies and the critical steps manufacturers should take to prepare for a range of evolving policy scenarios. (May 2026)
Download the White Paper
"*" indicates required fields